Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise in shrinking breast tumors before surgery

NCT ID NCT07396324

Recruiting now Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Feb 10, 2026 · Last updated May 16, 2026 · Updated 13 times

Summary

This study is testing whether adding a new immunotherapy drug (QL1706) to standard chemotherapy before surgery can help eliminate tumors in people with hormone receptor-positive, HER2-negative breast cancer. About 55 adults with early-stage disease will receive the combination, and researchers will measure how many achieve a complete response (no cancer left in the tissue). The goal is to improve outcomes while monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Renji Hospital, School of Medicine, Shanghai Jiaotong University

    RECRUITING

    Shanghai, 200127, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER HR-POSITIVE/HER2-NEGATIVE BREAST CANCER